JW중외제약

001060KOSPI의약품 제조업

59.6 / 100

Reference Date: 2026-04-13

Financial Score23.5 / 40

News Sentiment12.1 / 25

Momentum14.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but Operating Profit is on a declining trend. Slightly up 1.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

JW Chungwa Pharmaceutical focuses on the research, development, manufacturing, and sales of pharmaceuticals, leveraging a strong pipeline of original drugs such as Rivaro and Winnerf, along with a global R&D network. The company offers a diverse range of specialty and over-the-counter medications, as well as healthcare products, maintaining a competitive edge in both domestic and international markets.

Number of Employees

1,106people

Average Salary

64.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

12.71Industry Average 14.805.0Point

In line with industry avg

PBR

2.03Industry Average 1.041.0Point

2.0x industry avg (risky)

ROE

17.60Industry Average 4.427.0Point

4.0x industry avg (excellent)

Debt Ratio

7.24Industry Average 11.985.0Point

Lower than industry avg (good)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼1.6% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 18.4% (improving, 3yr)

Detailed News Sentiment

29 totalPositive 3Neutral 18Negative 3Average Sentiment Score 48.1

Detailed Momentum

52-week position6.0Point

52w upper range (62%)

Current 32,200Won52-week high 39,05052-week low 20,950

1-month return3.0Point

1m 1.42% (flat)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral투자판단관련주요경영사항2026-04-08
Neutral기업가치제고계획(자율공시)2026-03-27
Neutral정기주주총회결과2026-03-26
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral사업보고서 (2025.12)2026-03-18